

# HOT TOPICS & CONTROVERSIES IN PARKINSON'S DISEASE

**Melissa J. Nirenberg, MD, PhD, FAAN**  
NYU School of Medicine  
New York, NY

**Alberto J. Espay, MD, MSc, FAAN**  
University of Cincinnati

**The goal of this course is for speakers and participants to bring their own experiences and backgrounds to teach and generate discussion about the diagnosis and management of Parkinson's disease.** This will be accomplished through a combination of rapid-fire discussion of hot topics, as well as more lengthy and substantive debates on some of the areas of greatest controversy in the field.

**The course is aimed at participants of all backgrounds and levels of experience.** Audience participation will be strongly encouraged, so that participants can introduce their personal experiences, opinions, questions, and perspectives into the mix. Members of the audience will be given the opportunity to indicate how they would manage various clinical scenarios both before and after the discussion, and see how the course may influence their future approaches to patient care.

**There is no real "syllabus" for this course,** as the purpose is not to provide a single answer to each question, but rather to stimulate an interesting, dynamic, and thought-provoking discussion that will enable participants to draw their own conclusions based on current knowledge and the evidence-based literature.

## **Suggested references:**

### Practice parameters & evidence-based reviews:

1. Chou YH, Hickey PT, Sundman M, Song AW, Chen NK. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol.* 2015; 72(4):432-440.
2. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. *JAMA.* 2014; 30; 311(16):1670-83.
3. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. *Eur J Neurol.* 2013; 20(1):5-15
4. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. *Mov Disord* 2011; 26(S3):S2-SS41, and 2015 online update: <http://www.movementdisorders.org/MDS/Resources/Publications-Reviews/EBM-Reviews1.htm>.
5. Koppel, BS. Brust JCM, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. *Neurology* 2014; 82(17): 1556-1563.
6. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2002; 58:11-17.
7. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; 66:996-1002.
8. *Movement Disorders Journal: Special Issue: New Treatments in Parkinson Disease and Movement Disorders.* 2015; 30(11): 1442-1520.
9. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2006; 66:983-995.
10. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. *Mov Disord* 2011; 26 Suppl 3:S42-80, and 2012 online update. See [http://display.mds.prod.titanclient.com/MDS-Files1/PDFs/EBM-Papers/EBM\\_NMS\\_Updated\\_15Jan2014.pdf](http://display.mds.prod.titanclient.com/MDS-Files1/PDFs/EBM-Papers/EBM_NMS_Updated_15Jan2014.pdf)

11. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2010; 74:924-931.

#### **Other Suggested References:**

1. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *Lancet*. 2014; 383(9916):533-40.
2. de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. *Neurology* 2012;78:696-701.
3. Elias WJ, Huss D, Voss T, Loomba J, Khaled M, Zadicario E, Frysinger RC, Sperling SA, Wylie S, Monteith SJ, Druzgal J, Shah BB, Harrison M, Wintermark M. A pilot study of focused ultrasound thalamotomy for essential tremor. *N Engl J Med*. 2013; 39:640-648.
4. Fox SH, Marras C. Orthostatic hypotension in Parkinsonism: What is it and how can we treat it? *Mov Disord*. 2015; 30(5): 601-603.
5. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). *Mov Disord*. 2015; 5; 30(5):646-54.
6. Nirenberg MJ and Fernandez HH, Overview of Parkinson's Disease course syllabus, American Academy of Neurology meeting 2017.
7. Olanow CW, Rascol O, Hauser RA, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. *NEJM* 2009; 361:1268-1278.
8. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanaganas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol*. 2014; 13(2):141-149.
9. Pagan F, Hebron M, Valadez EH, et al. Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. *Journal of Parkinson's disease* 2016;6:503-517.
10. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. *JAMA*. 2000; 284:1931-1938.
11. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. *N Engl J Med*. 2004; 351:2498-2508.
12. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. *Arch Neurol* 2010; 67:58-63.
13. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. *N Engl J Med*. 2000; 342:1484-1491.
14. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? *Ann Neurology*. 2006; 59:559-562.
15. Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. *Neurodegener Dis* 2013; 11:63-71.
16. Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. *Nat Rev Neurol* 2017 Jan 20 [Epub ahead of print].
17. Espay AJ, Lang AE, Erro R, Merola A, Fasano A, Berardelli A, Bhatia KP. Essential pitfalls in "essential" tremor. *Mov Disord* 2017 Jan 24 [Epub ahead of print].
18. Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. *Lancet Neurol* 2016 Aug;15(9):954-966.